Literature DB >> 31072719

Hill-Sachs Lesion Classification by the Glenoid Track Paradigm in Shoulder Instability: Poor Agreement Between 3-Dimensional Computed Tomographic and Arthroscopic Methods.

Tadanao Funakoshi1, Robert U Hartzler2, Eduardo Stewien3, Stephen S Burkhart4.   

Abstract

PURPOSE: The purpose of this study was to determine the amount of agreement between preoperative 3-dimensional computed tomographic (3D-CT) and intraoperative arthroscopic classification of Hill-Sachs lesions (HSLs) according to the glenoid track (GT) paradigm.
METHODS: Records for patients treated surgically for anterior shoulder instability from a single surgeon's practice from August 2013 until March 2016 were retrospectively reviewed. Inclusion criteria were presence of an HSL, < 25% glenoid bone loss, bilateral 3D-CT, and arthroscopically recorded bone loss measurements. Records for patients with chronic dislocations or prior operations were excluded. Calculations by 3D-CT and arthroscopy were performed as follows: Hill-Sachs interval (HSI) was the distance from rotator cuff insertion to medial edge of the HSL; GT was 83% of the normal glenoid width minus any glenoid defect; on-track was HSI less than GT; off-track was HSI greater than GT.
RESULTS: Sixteen shoulders with HSL status determined as on- or off-track demonstrated agreement between the 2 methods in 10 of 16 cases (63%, Cohen's κ = 0.16). All 6 cases with disagreement were calculated as on-track by 3D-CT and off-track by arthroscopic measurement. The GT was larger as determined by 3D-CT measurement (22 ± 1 mm [21-24]) compared with arthroscopy (18 ± 1 mm [17-20], P = .002).
CONCLUSIONS: Preoperative 3D-CT showed slight agreement compared with intraoperative arthroscopic measurements in classifying HSL as on-track versus off-track in the GT paradigm; larger GT size by 3D-CT versus arthroscopy accounted for all discrepancies. Determination of off-track status based on preoperative 3D-CT versus determination with the arthroscopic method would result in fewer HSLs treated with remplissage if the GT treatment paradigm were followed. Surgeons using the GT paradigm to determine treatment of HSL by remplissage should recognize the potential for discordance between arthroscopic and radiographic measurements.
Copyright © 2019 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31072719     DOI: 10.1016/j.arthro.2018.12.005

Source DB:  PubMed          Journal:  Arthroscopy        ISSN: 0749-8063            Impact factor:   4.772


  5 in total

1.  Reliability of humeral head measurements performed using two- and three-dimensional computed tomography in patients with shoulder instability.

Authors:  Jakub Stefaniak; A M Kubicka; A Wawrzyniak; L Romanowski; P Lubiatowski
Journal:  Int Orthop       Date:  2020-07-26       Impact factor: 3.075

2.  Characterization of Infraspinatus Tendon Anatomy: The Soft-Tissue Portion of Remplissage.

Authors:  Thomas J Kremen; Carl-Henri Monfiston; John M Garlich; Milton T M Little; Melodie F Metzger
Journal:  Arthrosc Sports Med Rehabil       Date:  2021-03-15

3.  Evaluation of the Glenoid Track Tomographic Method in Magnetic Resonance Imaging/Arthro-MRI.

Authors:  Andre Couto Godinho; Pedro Couto Godinho; Flávio de Oliveira França; Elísio José Salgado Ribeiro; Daniel Carvalho de Toledo; Guilherme Henrique Franco
Journal:  Rev Bras Ortop (Sao Paulo)       Date:  2020-10-29

Review 4.  Imaging Modalities for the Glenoid Track in Recurrent Shoulder Instability: A Systematic Review.

Authors:  Matthew L Vopat; Christina A Hermanns; Kaare S Midtgaard; Jordan Baker; Reed G Coda; Sana G Cheema; Armin Tarakemeh; Liam Peebles; Bryan G Vopat; Matthew T Provencher
Journal:  Orthop J Sports Med       Date:  2021-06-03

5.  Management of bone loss in recurrent traumatic anterior shoulder instability: a survey of North American surgeons.

Authors:  Aaron J Bois; Michelle J Mayer; Stephen D Fening; Morgan H Jones; Anthony Miniaci
Journal:  JSES Int       Date:  2020-05-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.